Log in

Relevant bibliographies by topics / Syk Inhibitor

Contents

Journal articles
Dissertations / Theses
Books
Book chapters
Conference papers

Academic literature on the topic 'Syk Inhibitor'

Author: Grafiati

Published: 11 March 2023

Last updated: 31 July 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Syk Inhibitor.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Syk Inhibitor"

1

Wang, Xing, Junfang Guo, Zhongqi Ning, and Xia Wu. "Discovery of a Natural Syk Inhibitor from Chinese Medicine through a Docking-Based Virtual Screening and Biological Assay Study." Molecules 23, no. 12 (2018): 3114. http://dx.doi.org/10.3390/molecules23123114.

Full text

Abstract:

Spleen tyrosine kinase (Syk) is a critical target protein for treating immunoreceptor signalling-mediated allergies. In this study, a virtual screening of an in-house Chinese medicine database followed by biological assays was carried out to identify novel Syk inhibitors. A molecular docking method was employed to screen for compounds with potential Syk inhibitory activity. Then, an in vitro kinase inhibition assay was performed to verify the Syk inhibitory activity of the virtual screening hits. Subsequently, a β-hexosaminidase release assay was conducted to evaluate the anti-mast cell degran

APA, Harvard, Vancouver, ISO, and other styles

2

Zhao, Xiaoxian, Andrew E. Schade, and Eric Hsi. "Distinct Role of Src Family Kinase Inhibitors in Burkitt Lymphoma Cells Vs. Diffuse Large B-Cell Lymphoma Cells." Blood 112, no. 11 (2008): 3765. http://dx.doi.org/10.1182/blood.v112.11.3765.3765.

Full text

Abstract:

Abstract Introduction: The Non-Hodgkin lymphomas (NHLs) are a heterogeneous group of malignancies, with approximately 85% of NHL belonging to the B-cell lineage. Src family kinases (SFKs) are non-receptor intracellular tyrosine kinases which are important in the regulation of multiple signaling pathways including cell proliferation, tumor invasiveness, angiogenesis and apoptosis. Syk is another predominant tyrosine kinase expressed in B-cell lines in addition to SFKs. We attempted to correlate SFK and Syk inhibitor efficacy with the presence of phospho-SFK or phospho-Syk in lymphoma cell lines

APA, Harvard, Vancouver, ISO, and other styles

3

Buchner, Maike, Simon Fuchs, Gabriele Prinz, et al. "Spleen Tyrosine Kinase (SYK) Is Overexpressed and Represents a Potential Therapeutic Target in Chronic Lymphocytic Leukemia." Blood 112, no. 11 (2008): 543. http://dx.doi.org/10.1182/blood.v112.11.543.543.

Full text

Abstract:

Abstract B cell chronic lymphocytic leukemia (CLL), the most prevalent B cell malignancy in adults, is characterized by expansion of monoclonal mature B lymphocytes. Despite advances in treatment, the disease remains incurable warranting further efforts to identify novel molecular targets in CLL. B cell receptor (BCR) signaling contributes to apoptosis resistance in CLL limiting the efficacy of therapeutic approaches. In this study we investigated the expression of spleen tyrosine kinase (SYK), a key component of the BCR signaling pathway, in CLL and its role in apoptosis. Gene expression prof

APA, Harvard, Vancouver, ISO, and other styles

4

Bertoni, Francesco, Andrea Rinaldi, Anna Sasso, et al. "In Vitro Activity of SYK and BCR-ABL Inhibitors in Aggressive Lymphomas." Blood 108, no. 11 (2006): 2520. http://dx.doi.org/10.1182/blood.v108.11.2520.2520.

Full text

Abstract:

Abstract The B cell receptor tyrosine kinase SYK is a critical component of the B-cell receptor signalling pathway in normal B cells. We have recently reported that SYK is amplified and over-expressed in mantle cell lymphoma (MCL) and that the growth of MCL and diffuse large B cell lymphoma (DLBCL) cell lines over-expressing SYK is inhibited by piceatannol, a known SYK inhibitor (Bertoni et al, ASH 2005; Rinaldi et al, BJH 2006). Others have reported important SYK expression in splenic marginal zone B cell lymphomas, in DLBCL and peripheral T cell lymphomas (PTCL) (Ruiz-Ballesteros et al, 2005

APA, Harvard, Vancouver, ISO, and other styles

5

Huang, Duen-Yi, Wei-Yu Chen, Chi-Long Chen, Nan-Lin Wu, and Wan-Wan Lin. "Synergistic Anti-Tumour Effect of Syk Inhibitor and Olaparib in Squamous Cell Carcinoma: Roles of Syk in EGFR Signalling and PARP1 Activation." Cancers 12, no. 2 (2020): 489. http://dx.doi.org/10.3390/cancers12020489.

Full text

Abstract:

Syk is a non-receptor tyrosine kinase involved in the signalling of immunoreceptors and growth factor receptors. Previously, we reported that Syk mediates epidermal growth factor receptor (EGFR) signalling and plays a negative role in the terminal differentiation of keratinocytes. To understand whether Syk is a potential therapeutic target of cancer cells, we further elucidated the role of Syk in disease progression of squamous cell carcinoma (SCC), which is highly associated with EGFR overactivation, and determined the combined effects of Syk and PARP1 inhibitors on SCC viability. We found th

APA, Harvard, Vancouver, ISO, and other styles

6

Coates, Matthew S., Eric W. F. W. Alton, Garth W. Rapeport, Jane C. Davies, and Kazuhiro Ito. "Pseudomonas aeruginosa induces p38MAP kinase-dependent IL-6 and CXCL8 release from bronchial epithelial cells via a Syk kinase pathway." PLOS ONE 16, no. 2 (2021): e0246050. http://dx.doi.org/10.1371/journal.pone.0246050.

Full text

Abstract:

Pseudomonas aeruginosa (Pa) infection is a major cause of airway inflammation in immunocompromised and cystic fibrosis (CF) patients. Mitogen-activated protein (MAP) and tyrosine kinases are integral to inflammatory responses and are therefore potential targets for novel anti-inflammatory therapies. We have determined the involvement of specific kinases in Pa-induced inflammation. The effects of kinase inhibitors against p38MAPK, MEK 1/2, JNK 1/2, Syk or c-Src, a combination of a p38MAPK with Syk inhibitor, or a novel narrow spectrum kinase inhibitor (NSKI), were evaluated against the release

APA, Harvard, Vancouver, ISO, and other styles

7

Makhoul, Stephanie, Stephanie Dorschel, Stepan Gambaryan, Ulrich Walter, and Kerstin Jurk. "Feedback Regulation of Syk by Protein Kinase C in Human Platelets." International Journal of Molecular Sciences 21, no. 1 (2019): 176. http://dx.doi.org/10.3390/ijms21010176.

Full text

Abstract:

The spleen tyrosine kinase (Syk) is essential for immunoreceptor tyrosine-based activation motif (ITAM)-dependent platelet activation, and it is stimulated by Src-family kinase (SFK)-/Syk-mediated phosphorylation of Y352 (interdomain-B) and Y525/526 (kinase domain). Additional sites for Syk phosphorylation and protein interactions are known but remain elusive. Since Syk S297 phosphorylation (interdomain-B) was detected in platelets, we hypothesized that this phosphorylation site regulates Syk activity via protein kinase C (PKC)-and cyclic adenosine monophosphate (cAMP)-dependent pathways. ADP,

APA, Harvard, Vancouver, ISO, and other styles

8

Issara-Amphorn, Jiraphorn, Naraporn Somboonna, Prapaporn Pisitkun, Nattiya Hirankarn, and Asada Leelahavanichkul. "Syk inhibitor attenuates inflammation in lupus mice from FcgRIIb deficiency but not in pristane induction: the influence of lupus pathogenesis on the therapeutic effect." Lupus 29, no. 10 (2020): 1248–62. http://dx.doi.org/10.1177/0961203320941106.

Full text

Abstract:

Macrophages are responsible for the recognition of pathogen molecules. The downstream signalling of the innate immune responses against pathogen molecules, lipopolysaccharide (LPS) and (1→3)-β-D-glucan (BG), and the adaptive immune response to antibodies, Fc gamma receptor (FcgR), is spleen tyrosine kinase (Syk). Because pathogen molecules and antibodies could be presented in lupus, impact of Syk and macrophages in lupus is explored. FcgR-IIb deficient (FcgRIIb-/-) mice, a model of inhibitory signalling loss, at 40 weeks old, but not pristane mice (a chemical induction lupus model) demonstrate

APA, Harvard, Vancouver, ISO, and other styles

9

Getz, Todd M., Bhanu Manne, Lorena Buitrago, Yingying Mao, and Satya P. Kunapuli. "Dextran sulphate induces fibrinogen receptor activation through a novel Syk-independent PI-3 kinase-mediated tyrosine kinase pathway in platelets." Thrombosis and Haemostasis 109, no. 06 (2013): 1131–40. http://dx.doi.org/10.1160/th12-09-0645.

Full text

Abstract:

SummaryIn our attempt to find a physiological agonist that activates PAR3 receptors, we screened several coagulation proteases using PAR4 null platelets. We observed that FXIIa and heat inactivated FXIIa, but not FXII, caused platelet aggregation. We have identified a contaminant activating factor in FXIIa preparation as dextran sulfate (DxS), which caused aggregation of both human and mouse platelets. DxS-induced platelet aggregation was unaffected by YM254890, a Gq inhibitor, but abolished by pan-Src family kinase (SFK) inhibitor PP2, suggesting a role for SFKs in this pathway. However, DxS-

APA, Harvard, Vancouver, ISO, and other styles

10

Kiliszek, Przemyslaw, Maciej Szydlowski, Tomasz Sewastianik, et al. "FOXO1 Activation Is an Effector of SYK and AKT Inhibition in Tonic BCR Signal-Dependent Diffuse Large B-Cell Lymphomas." Blood 126, no. 23 (2015): 314. http://dx.doi.org/10.1182/blood.v126.23.314.314.

Full text

Abstract:

Abstract Introduction: In normal B lymphocytes, B-cell receptor (BCR)-induced activation of PI3K-AKT kinases and subsequent inactivation of FOXO1 is a critical pro-survival component of tonic BCR signaling. In murine models, conditional deletion of FOXO1 protected quiescent peripheral B cells from apoptosis mediated by inducible loss of the BCR, demonstrating that PI3K-AKT-FOXO1 axis plays a central role in B-cell homeostasis. Disruption of the BCR signaling by SYK inhibitor leads also to the apoptosis of BCR-dependent DLBCLs, at least in part via a mechanism involving decreased activity of PI

APA, Harvard, Vancouver, ISO, and other styles

More sources

Dissertations / Theses on the topic "Syk Inhibitor"

1

Yamamoto, Noriyuki. "Development of a selective inhibitor for Syk tyrosine kinase and investigation of its pharmacological activities." 京都大学 (Kyoto University), 2003. http://hdl.handle.net/2433/148369.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Roders, Nathalie. "Régulation de l'activation de lymphocytes B / cellules plasmatiques pendant le rejet chronique : Le rôle de SYK dans la modulation de Mcl-1." Thesis, Université Paris-Saclay (ComUE), 2017. http://www.theses.fr/2017SACLS439/document.

Full text

Abstract:

L'insuffisance rénale est un problème majeur de santé publique et la transplantation rénale est l’option thérapeutique principale, mais elle comporte le risque de rejet d'organe. Les cellules B jouent un rôle important dans le rejet médié par les anticorps (AMR). Au cours de l'AMR chronique, les structures lymphoïdes tertiaires, semblables aux centres germinatifs (GC), apparaissent dans l'organe rejeté, associées à la production des plasmocytes et des lymphocytes B mémoires spécifiques du donneur. Ces populations de lymphocyte B sont souvent mal contrôlées par les traitements actuels. La myelo

APA, Harvard, Vancouver, ISO, and other styles

3

Abadleh, Mohammed Mustafa Mohammed. "Diarylisoxazole als Leitstruktur für Design und Synthese von Proteinkinase Inhibitoren = Diarylisoxazoles as lead for the design and synthesis of protein kinase inhibitors /." Tübingen, 2009. http://opac.nebis.ch/cgi-bin/showAbstract.pl?sys=000276718.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Xu, Mingming. "Discovery of inhibitors against a-synuclein aggregation." Thesis, Griffith University, 2020. http://hdl.handle.net/10072/392373.

Full text

Abstract:

Abnormal protein aggregation has been linked to many neurodegenerative diseases, including Parkinson’s disease (PD). The main pathological hallmark of PD is the formation of Lewy bodies and Lewy neurites, both containing the pre-synaptic protein α-synuclein (α-syn). Native α-syn, under normal conditions, exists in a soluble unfolded state but undergoes misfolding and aggregation into toxic aggregates under pathological conditions. Toxic α-syn species can cause oxidative stress, membrane penetration, synaptic and mitochondrial dysfunction, leading to neuronal death and eventually neurodegenerat

APA, Harvard, Vancouver, ISO, and other styles

5

Coombes, Susan. "Boards of directors and nonprofit entrepreneurial orientation Catalyst, inhibitor, or inconsequential /." Related electronic resource: Current Research at SU : database of SU dissertations, recent titles available full text, 2008. http://wwwlib.umi.com/cr/syr/main.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Bracht, Kathrin. "Neue Inhibitoren zellmembranständiger Proteinkinasen /." Konstanz, 2008. http://opac.nebis.ch/cgi-bin/showAbstract.pl?sys=000252796.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Cohen, Jason C. "Attention mechanisms and inhibition of return in the somatosensory system." Related electronic resource: Current Research at SU : database of SU dissertations, recent titles available full text, 2002. http://wwwlib.umi.com/cr/syr/main.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Amanovic, Ilijana. "Ginkgo biloba extract inhibits tissue factor degradation /." [S.l.] : [s.n.], 2009. http://opac.nebis.ch/cgi-bin/showAbstract.pl?sys=000278514.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Wollmann, Heike. "MiRNA targeting mechanisms - translation inhibition versus transcript cleavage /." Tübingen, 2009. http://opac.nebis.ch/cgi-bin/showAbstract.pl?sys=000251923.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Rango, Enrico. "PRECLINICAL CHARACTERIZATION OF SFK INHIBITORS, PYRAZOLO[3,4-d]PYRIMIDINE SCAFFOLD-BASED DERIVATIVES, FOR CANCER TREATMENT." Doctoral thesis, Università di Siena, 2021. http://hdl.handle.net/11365/1140389.

Full text

Abstract:

The first part of this thesis essentially focuses on the preclinical characterization of Si306, a pyrazolo[3,4-d]pyrimidine derivative, identified as a very promising anticancer agent. This compound has shown a favorable in vitro and in vivo activity profile against neuroblastoma (NB) and glioblastoma (GBM) models by acting as a competitive inhibitor of c-Src tyrosine kinase. Nevertheless, the good antitumor activity of Si306 is associated with sub-optimal aqueous solubility, which might hinder its further development. In this context, drug delivery systems were developed to overcome the poor

APA, Harvard, Vancouver, ISO, and other styles

More sources

Books on the topic "Syk Inhibitor"

1

Remer, Imke Ilina. Syk-Inhibition mit Fostamatinib reduziert die Makrophagenakkumulation in atherosklerotischen Plaques. s.n.], 2014.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

2

Fleischmann, Roy. Signalling pathway inhibitors. Oxford University Press, 2013. http://dx.doi.org/10.1093/med/9780199642489.003.0081.

Full text

Abstract:

Oral, small-molecule signalling pathway inhibitors, including ones that inhibit the JAK and SyK pathways, are currently in development for the treatment of rheumatoid arthritis (RA). Tofacitinib is an orally administered small-molecule inhibitor that targets the intracellular Janus kinase 3 and 1 (JAK1/3) molecules to a greater extent than JAK2 while baricitinib (formerly INCB028050) predominantly inhibits JAK1/2. Many of the proinflammatory cytokines implicated in the pathogenesis of RA utilize cell signalling that involves the JAK-STAT pathways and therefore inhibition of JAK-STAT signalling

APA, Harvard, Vancouver, ISO, and other styles

Book chapters on the topic "Syk Inhibitor"

1

Ishida, Yoji. "Others (Syk Inhibitor and Other Medications)." In Autoimmune Thrombocytopenia. Springer Singapore, 2017. http://dx.doi.org/10.1007/978-981-10-4142-6_18.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Denyer, Jane, and Vipul Patel. "Syk kinase inhibitors." In New Drugs and Targets for Asthma and COPD. KARGER, 2010. http://dx.doi.org/10.1159/000320832.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Ayna, Adnan. "Clinical Aspects and Treatment of Parkinson Disease: a Biochemical Perspective." In Neurological Diseases and Treatments in Terms of Biochemistry. Nobel Tip Kitabevleri, 2024. http://dx.doi.org/10.69860/nobel.9786053359357.9.

Full text

Abstract:

Parkinson disease (PD), among one of the most prevalent neurodegenerative illness, affecting around 2-3% of people over the age of 65. PD is characterized by intra-cellular aggregates of α-synuclein (syn) and neuron cell loss in the brain region of substantia nigra (SN), which results in deficiency in dopamine levels. Several other types of cell in the peripheral and central autonomic nerve are also involved, most probably from the beginning of the disease. PD is associated with numerous non-motor indicators that donate to overall infirmity, despite the fact a medical diagnosis of the ailment

APA, Harvard, Vancouver, ISO, and other styles

4

Ihlein, Lucas. "Agricultural Inventiveness." In Covert Plants. punctum books, 2018. https://doi.org/10.21983/p3.0207.1.17.

Full text

Abstract:

In 2014, I began working on a collaborative art project called Sug-ar vs the Reef? The project came about following an invitation from John Sweet, a retired farmer and active community worker in the Queensland town of Mackay. Sweet’s hunch was that the involvement of artists in a complex environmental management problem might help to catalyse positive transformations in the sugar cane industry, which is often accused of polluting the pris-tine waters of the Great Barrier Reef with agricultural run-off.1This chapter is based on some of the early field research for Sugar vs the Reef? and my task

APA, Harvard, Vancouver, ISO, and other styles

5

Fleischmann, Roy. "Signalling pathway inhibitors." In Oxford Textbook of Rheumatology. Oxford University Press, 2013. http://dx.doi.org/10.1093/med/9780199642489.003.0081_update_003.

Full text

Abstract:

Oral, small-molecule signalling pathway inhibitors, including ones that inhibit the JAK and other pathways, are currently in development for the treatment of rheumatoid arthritis (RA). Many of the pro-inflammatory cytokines implicated in the pathogenesis of RA utilize cell signalling that involves the JAK-STAT pathways and therefore inhibition of JAK-STAT signalling, by targeting multiple RA-associated cytokine pathways, has the potential to simultaneously reduce inflammation, cellular activation, and proliferation of key immune cells. Spleen tyrosine kinase (SyK) is a cytoplasmic tyrosine kin

APA, Harvard, Vancouver, ISO, and other styles

6

Carlsson Enar. "The Omeprazole Story: How Endurance in Research May Pay Off." In Solvay Pharmaceuticals Conferences. IOS Press, 2008. https://doi.org/10.3233/978-1-58603-949-3-101.

Full text

Abstract:

Based on the dictum: No acid &ndash; no ulcer a number of pharmaceutical companies started up research aiming at a drug, inhibiting gastric acid secretion during 1960s. The focus of that research was gastrin, the gastric acid stimulating hormone released from G-cells in the antral part of the stomach. The Searle company in the US tried to find a small molecule inhibiting the gastrin receptor, while AstraH&auml;ssle in Sweden tried to find something that decreased the release of gastrin from the G-cells. SK&amp;F focused on the H2-receptor also involved in the regulation of gastric

APA, Harvard, Vancouver, ISO, and other styles

7

Singh, Rajinder, and Esteban S. Masuda. "Chapter 24 Spleen Tyrosine Kinase (Syk) Biology, Inhibitors and Therapeutic Applications." In Annual Reports in Medicinal Chemistry Volume 42. Elsevier, 2007. http://dx.doi.org/10.1016/s0065-7743(07)42024-3.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Erdoğan, Tuba, and Uğur Muşabak. "Alerjiye Bağlı Alt Ekstremite Ödemi (Anjioödem)." In Alt Ekstremite Ödemi. İstanbul Üniversitesi–Cerrahpaşa Yayınevi, 2024. http://dx.doi.org/10.5152/7609.

Full text

Abstract:

Anjioödem (AÖ), mukoza, submukoza ve subkutanöz dokulardaki lokalize kendini sınırlayan gode bırakmayan şişliklerdir. Anjioödem altta yatan etiyolojiye göre mast hücre mediatörleri ilişkili (histaminerjik), bradikinin ilişkili (non-histaminerjik) ve idiyopatik olarak üç ana forma ayrılır. Histaminerjik AÖ en sık görülen formdur. Bradikinin ilişkili AÖ, C1 inhibitör eksikliği/ fonksiyon bozukluğu, altta yatan hastalıklar ya da ilaç kullanımına bağlı gelişebilir. Klinik bulguları benzer olsa da altta yatan mekanizmanın bilinmesi etkin tedavinin seçilmesi açısından önemlidir. Histaminerjik AÖ, st

APA, Harvard, Vancouver, ISO, and other styles

9

Spreen, Otfried, Anthony H. Risser, and Dorothy Edgell. "Convulsive Disorders." In Developmental Neuropsychology. Oxford University PressNew York, NY, 1995. http://dx.doi.org/10.1093/oso/9780195067361.003.0020.

Full text

Abstract:

Abstract A common denominator for the set of disorders discussed in this chapter is involvement of abnormal electrical activity, or discharge, of cerebral neurons. The terms “convulsions,” “seizures,” and “epilepsy” are sometimes used syn onymously, but do not necessarily refer to the same phenomenon. For the sake of uniformity in this chapter, the term “convulsive disorder” is used when we are discussing abnormal discharges in brain cells. These electrical changes, ex tracellularly recorded as EEG paroxysms, are thought to be summations of syn chronously developing depolarizations and hyperpo

APA, Harvard, Vancouver, ISO, and other styles

10

Pennington, M. W., W. R. Kem, and E. Karlsson. "Sea anemone potassium channel toxins." In Guidebook to Protein Toxins and Their Use in Cell Biology. Oxford University PressOxford, 1997. http://dx.doi.org/10.1093/oso/9780198599555.003.0057.

Full text

Abstract:

Abstract During screening for dendrotoxin-like compounds in marine organisms, extracts of several sea anemones were found to inhibit the binding of 125I-dendrotoxin I, a probe for voltage dependent potassium channels, to rat brain synaptosomal membranes (Harvey et al. 1991; Karlsson et al. 1991). Two toxins were later isolated from Carib¬ bean sea anemones, ShK toxin from Stichodactyla helianthus (Karlsson et al. 1992; Aneiros et al. 1993; Castaneda et al. 1995) and BgK toxin from Bunodosoma granulifera (Karlsson et al. 1992). More recently, another toxin has been isolated from Anemonia sulcat

APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Syk Inhibitor"

1

Dai, Changhong, Yue Yuan, Xinuo Huang, and Yanjiang Wang. "Prediction of Excitatory and Inhibitory Connections in the Human Brain Based on SDK-GAN." In 2024 IEEE 17th International Conference on Signal Processing (ICSP). IEEE, 2024. https://doi.org/10.1109/icsp62129.2024.10846423.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Agarwal, D. C., and Helena Alves. "Applications of Alloy 59 (UNS N06059) and Alloy 31 (UNS N08031) in Mitigating Corrosion Problems in CPI and Petrochemical Industries." In CORROSION 2007. NACE International, 2007. https://doi.org/10.5006/c2007-07186.

Full text

Abstract:

Abstract CPI & Petrochemicals constitute a huge, complex and highly diverse industry which forms an integral part of the US economy. It covers converting various raw materials (about 10 of them), the most important ones being organic in nature such as oil, natural gas and coal whilst others are inorganic in nature such as ores / elements taken from the earth (phosphates, sulfur, potash etc), air (nitrogen, oxygen) and water (chlorine, hydrogen). Conversion of these base materials produce about 300 different “intermediates” which then go into production of about 30.000 plus consumer product

APA, Harvard, Vancouver, ISO, and other styles

3

Lamb, David, Katherina Sewald, Ewald Benediktus, and Armin Braun. "Evaluating a CD63 assay as a biomarker for SYK inhibitor activity." In ERS International Congress 2020 abstracts. European Respiratory Society, 2020. http://dx.doi.org/10.1183/13993003.congress-2020.3301.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Reddy, Sanjeeva, Nitin K. Damle, Aranapakam M. Venkatesan, et al. "Abstract 792: ASN002: A novel dual SYK/JAK inhibitor with strong antitumor activity." In Proceedings: AACR 106th Annual Meeting 2015; April 18-22, 2015; Philadelphia, PA. American Association for Cancer Research, 2015. http://dx.doi.org/10.1158/1538-7445.am2015-792.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Chow, Chung-Wai, Patricia Castellanos Penton, Michelle North, Hajera Amatullah, Xiaomin Wang, and Jeremy Scott. "Treatment With Syk Inhibitor Attenuates Airway Hyperresponsiveness In A Chronic Murine Model Of Asthma." In American Thoracic Society 2012 International Conference, May 18-23, 2012 • San Francisco, California. American Thoracic Society, 2012. http://dx.doi.org/10.1164/ajrccm-conference.2012.185.1_meetingabstracts.a2846.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Joshi, Shweta, Kevin Liu, Muamera Zulcic, et al. "Abstract 109: Myeloid Syk-PI3Kg-HIF axis inhibits anti-tumor adaptive immunity:In silicodesign of a “first in class” novel dual-Syk/PI3K inhibitor, SRX3207, to block the immunosuppressive tumor microenvironment." In Proceedings: AACR Annual Meeting 2019; March 29-April 3, 2019; Atlanta, GA. American Association for Cancer Research, 2019. http://dx.doi.org/10.1158/1538-7445.am2019-109.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Joshi, Shweta, Kevin Liu, Muamera Zulcic, et al. "Abstract 109: Myeloid Syk-PI3Kg-HIF axis inhibits anti-tumor adaptive immunity:In silicodesign of a “first in class” novel dual-Syk/PI3K inhibitor, SRX3207, to block the immunosuppressive tumor microenvironment." In Proceedings: AACR Annual Meeting 2019; March 29-April 3, 2019; Atlanta, GA. American Association for Cancer Research, 2019. http://dx.doi.org/10.1158/1538-7445.sabcs18-109.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Sappal, Jessica J., Matthew Theisen, Zhongmin Xiang, et al. "Abstract 3844: TAK-659, a SYK kinase inhibitor, demonstrates preclinical antitumor activity in solid tumor models." In Proceedings: AACR Annual Meeting 2018; April 14-18, 2018; Chicago, IL. American Association for Cancer Research, 2018. http://dx.doi.org/10.1158/1538-7445.am2018-3844.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Kim, Seon Uk, Hyun Jung Yoo, Shin Eui Kang, et al. "AB0126 ANTI-INFLAMMATORY EFFECTS OF SPLEEN TYROSINE KINASE (SYK) INHIBITOR, PICEATANNOL, ON FIBROBLAST-LIKE SYNOVIOCYTE IN RHEUMATOID ARTHRITIS." In Annual European Congress of Rheumatology, EULAR 2019, Madrid, 12–15 June 2019. BMJ Publishing Group Ltd and European League Against Rheumatism, 2019. http://dx.doi.org/10.1136/annrheumdis-2019-eular.6696.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Tannheimer, Stacey L., Adam Kashishian, Rick Sorensen, and Kathleen S. Keegan. "Abstract 2371: Entospletinib, a potent SYK inhibitor, blocks constitutive and FCgRI activated signaling in FLT3-ITD cell lines." In Proceedings: AACR Annual Meeting 2018; April 14-18, 2018; Chicago, IL. American Association for Cancer Research, 2018. http://dx.doi.org/10.1158/1538-7445.am2018-2371.

Full text

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!